Cite
MLA Citation
Daniel V T Catenacci et al.. “Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial.” Lancet oncology, vol. 21, no. 8, 2020, pp. 1066–1076. http://access.bl.uk/ark:/81055/vdc_100105903585.0x000013